期刊文献+

慢性淋巴细胞白血病患者免疫球蛋白重链片段及其突变状态的研究 被引量:2

Overrepresentation of specific gene segments of expressed immunoglobulin heavy chain variable region among unmutated and mutated patients with chronic lymphocytic leukemia
原文传递
导出
摘要 目的探讨我国慢性淋巴细胞白血病(CLL)患者免疫球蛋白重链可变区基因(IgVH)突变状态、基因偏颇性及其预后价值。方法应用多重PCR法检测CLL患者表达型IgVH片段使用情况及突变状态,并与患者生存和预后进行相关性分析。结果①共检测初诊CLL患者85例,80例(94.1%)成功测序。②IgVH片段的使用存在明显的偏颇性,其中常见的为VH3家族(32例,40.0%)、VH4家族(24例,30.0%),而VH5、VH6和VH7家族少见。VH4—39是最常见的VH基因片段。而J4和D3分别是JH家族和DH家族中使用频率最高的片段。③IgVH突变型56例(70.0%),非突变型24例(30.0%)。其中VH3家族突变率为90.7%(29例),VH4家族突变率为62.5%(15例)。④突变组与未突变组患者无进展生存时间(82个月和17个月,P=0.000)和总生存时间(90个月和41个月,P=0.009)差异均有统计学意义。⑤CLL患者IgVHCDR3区序列具重现性,2例VH片段为VH1-69的患者其CDR3序列与文献报道序列有很高的同源性。VH片段为VH1—18、VH3—7、VH3-23的患者中分别有2例CDR3序列完全相同。结论不同地区间CLL患者IgVH基因家族使用情况和突变状态存在一定差异,IgVH CDR3区序列具重现性,推测相对有限的抗原参与了CLL的发病。 Objective To investigate the oven:epresentation of specific gene segments of immunoglobulin heavy chain variable region (IgVH) among unmutated and mutated chronic lymphocytic leukemia (CLL) patients and its prognostic implication. Methods Multiplex PCR was used to identify the expression of IgVH segment and its mutation status in CLL. Results Analyses were successfully performed in 80 of 85 samples. Marked skewed IgVH families were disclosed. The most commonly used VH was VH3 (40.0%) , followed by VH4 (30.0%), VH1 ( 13.8% ), VH2 ( 10.0% ) and VH5 ,VH7 (2.5%). Fifty-six patients (70.0%) had mutated VH, 24 (30.0%) unmutated VH. Nine cases (11.3% ) were with 100% germline sequence. Fifteen cases ( 15/24,62.5% ) in VH4, 29 ( 29/32,90.7% ) in VH3, and 4 (4/11, 36.3% ) in VH1 had mutated VH. The most frequently used IgVH gene was VH4-39 ( 13.8% ) , and VH4-34 (8.8%). J4(36/66,54.5% ) and D3(25/66,37.8% )were the most frequently used in J and D genes. The progression-free survival (PFS) was 82 and 17 months (P=0. 000 ) , and the overall survival (OS) was 90 and 41 months( P = 0. 009) , respectively, for mutated and unmutated eases. Recurrent CDR3 sequences were found in our patients and 2 patients with VH1-69 had CDR3 sequences highly similar to those reported in literature. Conclusion There is difference in IgVH gene segment usage and mutational status in different area CLL patients. Recurrent CDR3 sequences were found in specific IgVH gene segments, which highlights the importance of immunoglobulin mediated stimulation in the development of CLL.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第8期529-532,共4页 Chinese Journal of Hematology
基金 国家科技支撑计划项目(2008BA161801) 国际科技合作项目(2010DFB30270) 天津市科技支撑计划项目(09ZCGYSF01000、09ZCZDSF03800)
关键词 白血病 淋巴细胞 慢性 聚合酶链反应 免疫球蛋白重链可变区 DNA突变分析 Leukemia,lymphocytic,chronic Polymerase chain reaction Immunoglobulin varia- ble heavy chain region DNA mutational analysis
  • 相关文献

参考文献9

  • 1Galimberti S, Morabito F, Guerrini F,et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular meth- od fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol, 2003, 120: 405-412.
  • 2Forconi F, Potter KN, Wheatley I, et al. The normal IGHV1-69- derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood, 2010,115:71-77.
  • 3Bomhen R, Dal-Bo M, Benedetti D, et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a dis- ease subset with peculiar clinical and biological features. Clin Cancer Res,2010, 16:620-628.
  • 4Szankasi P, Bahler DW. Clinical laboratory analysis of immuno- globulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. J Mol Diagn, 2010,12:244-249.
  • 5张亚平,陈丽娟,徐卫,乔纯,钱思轩,仇红霞,缪扣荣,刘红,李建勇.中国人群慢性淋巴细胞白血病免疫球蛋白重链可变区基因组成及突变分析[J].中华医学遗传学杂志,2009,26(2):196-199. 被引量:4
  • 6Mauerer K,Zahrieh D, Gorgun G, et al. Immunoglobulin gene seg- ment usage,location and immunogenicity in mutated and unmutat- ed chronic lymphocytic leukaemia. Br J Haematol, 2005,129 : 1499-1510.
  • 7Ironsa RD, Le A, Bao L,et al. Characterization of chronic lympho- cytic leukemia/small lymphocytic lymphoma(CLL/SLL) in Shang- hai, China: molecular and cytogenetic characteristics, IgV gene re- striction and hypermutation patterns. Leuk Res, 2009,33 : 1599- 1603.
  • 8Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treat- ment of chronic lymphocytic leukaemia. Nat Rev Cancer,2010, 10:37-50.
  • 9Tobin G, Thunberg U, Johnson A,et al. Chronic lymphocytic leu- kemia utilizing the VH3-21 gene display highly restricted Vlamb- da2-14 gene use and homologous CDR3s:implicating recognition of a common antigen epitope. Blood, 2003,101:4952-4957.

二级参考文献7

  • 1李丽,徐卫,李建勇.慢性淋巴细胞白血病预后因素研究进展[J].中华内科杂志,2006,45(9):781-783. 被引量:17
  • 2郑文娟,陈丽娟,吴雨洁,李丽,徐卫,李建勇.应用多重PCR技术检测慢性淋巴细胞白血病IgVH基因突变[J].中国实验血液学杂志,2006,14(6):1101-1104. 被引量:8
  • 3Mauerer K, Zahrieh D, Gorgun G, et al. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol, 2005, 129 : 499-510.
  • 4Widhopf GF, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood, 2004,104 : 2499-2504.
  • 5Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of ebronic lymphocytic leukemia. Blood, 2004,104 : 2879-2885.
  • 6Duke VM, Gandini D, Sherrington PD, et al. V(H) gene usage differs in germline and mutated B cell chronic lympaocytic leukemia. Haematologica, 2003,88: 1259-1271.
  • 7Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood, 2005,105 : 1678-1685.

共引文献3

同被引文献12

  • 1Lin TS. What is the optimal initial treatment for chronic lymphocytic leukemia?. Oncology ( Williston Park), 2007,21 : 1641-1649.
  • 2Hallek M,Cheson BD, Catovsky D,et aI. Guidelines for the diag- nosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia up- dating the National Cancer Institute-Working Group 1996 guide- lines. Blood,2008,111:5446-5456.
  • 3Flinn IW, Neuberg DS, Grever MR, et al. Phase ]II trial of flu- darabine plus cyclophosphamide compared with fludarabine for pa- tients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol,2007,25:793-798.
  • 4Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am Soc Hematol Educ Program, 2011,2011:104-109.
  • 5Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control,2012,19:37-53.
  • 6Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a muhivariate analysis from the randomized GCLLSG CLLS trial. J Clin Oncol, 2012,30:980-988.
  • 7Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet ,2010,376 : 1164-1174.
  • 8Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmuno- therapy may overcome the adverse prognostic significance of 11 q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer,2009,115:373-380.
  • 9Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclo- phosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood, 2011, 117,3016-3024.
  • 10Lin KI, Tam CS, Keating MJ, et al. Relevance of the immuno- globulin VH somatic mutation status in patients with chronic lym- phocytic leukemia treated with fiudarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood, 2009,113:3168-3171.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部